

# PRIME MEDICINE, Inc.

Fact Sheet

PRIME

LISTED

NASDAQ

# PRIME MEDICINE

## QUICK REFERENCE

Prime Medicine, Inc.

NASDAQ: PRIME

Website: [www.PRIMEMEDICINE.com](http://www.PRIMEMEDICINE.com)

## BUSINESS SUMMARY

Prime Medicine is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying its versatile, precise, effective and broad next generation gene editing technology, Prime Editing. Designed to make only the right edit at the right position within a gene, the Company's Prime Editing technology has broad therapeutic applications and is capable of repairing approximately 90 percent of known disease-causing mutations across many organisms, organs, and cell types. Prime Medicine has purposefully built a diversified portfolio organized around four strategic indication categories, with each set of indications chosen to deliver a different strategic goal, and is currently advancing a broad portfolio of therapeutic programs.

## BUSINESS OPERATIONS

Prime Editing technology, as developed by Dr. Liu and Dr. Anzalone, has broad theoretical potential therapeutic applications. For example, Prime Editing technology has the ability to repair diverse mutations, including all types of point mutations, deletion mutations, insertion and duplication mutations and insertion-deletion mutations. Our analysis of more than 75,000 pathological, or disease-causing, mutations found in the National Center for Biotechnology Information ClinVar Database shows that those addressable by Prime Editing technology account for approximately 90 percent of genetic variants associated with disease. As such, we believe Prime Editing technology has the theoretical potential for repairing approximately 90 percent of known disease-causing mutations across many organisms, organs and cell types. Because biotechnology companies can only initiate therapeutic programs for a subset of pathogenic mutations and the associated diseases, we have chosen to strategically focus on disease settings where we believe that Prime Editing technology could offer compelling advantages over both current standard-of-care and novel therapeutic modalities in development. Currently, at Prime Medicine, we are leveraging the breadth of our in-licensed Prime Editing technology to focus on our current portfolio of 18 therapeutic programs.

Prime Editors also have the ability to create permanent modifications at their natural genomic location, resulting in durable edits that are passed on to daughter cells, and retain their native physiological control. Our next generation gene editing technology is capable of a wide variety of precise, predictable and efficient genetic outcomes at the targeted sequence, while minimizing unwanted bystander edits and off-target edits and avoiding double-stranded DNA breaks. Our Prime Editors are designed to make only the right edit at the right position within a gene.

Our novel Prime Editors have two main components that act together to edit DNA: (i) a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and (ii) a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. Prime Editing leverages the established DNA-targeting capabilities of CRISPR-Cas proteins modified to nick, but not cause double-stranded DNA breaks, and combines these with the DNA synthesis capabilities of reverse transcriptase enzymes, which have been engineered to efficiently and precisely copy a pegRNA-encoded edited sequence into target DNA.

## CONTACT INFORMATION

US Headquarters  
21 Erie Street  
Cambridge, MA 02139

Barwicki Investor Relations Inc.  
Andrew Barwicki  
516-662-9461/[andrew@barwicki.com](mailto:andrew@barwicki.com)

## Recent Press Releases *(Headlines and Excerpts)*

### **Prime Medicine Announces Closing of Upsized Initial Public Offering**

Oct. 24, 2022 -- Prime Medicine, Inc. today announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of \$17.00 per share. The gross proceeds of the offering were approximately \$175.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Prime Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 shares of its common stock at the initial public offering price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol "PRME." All shares in the offering were offered by Prime Medicine.

J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

### **Prime Medicine Appoints Three New Directors to its Board of Directors**

August 11, 2022 – Prime Medicine, Inc. announced that Wendy Chung, M.D., Ph.D., Kaye Foster and Michael A. Kelly have been appointed to the company's board of directors.

Wendy Chung, M.D., Ph.D., is an American Board of Medical Genetics certified clinical and molecular geneticist and leads the Precision Medicine Resource in the Irving Institute at Columbia University, a position she has held since February 2014. Dr. Chung has been on the faculty at Columbia University since 2002, most recently as the Kennedy Family Professor of Pediatrics and Medicine at Columbia University, a position she has held since July 2017. Prior to that, she was an Associate Professor at Columbia University. She received her B.A. in biochemistry from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. in genetics from The Rockefeller University.

Kaye Foster, MBA, has been a Senior Advisor at the Boston Consulting Group since August 2014. Previously, she was Senior Vice President, Global Human Resources at Onyx Pharmaceuticals, Inc., where she led all aspects of human resources for U.S. and global operations. Prior to joining Onyx, Ms. Foster was Global Vice President of Human Resources and an Executive Committee member at Johnson & Johnson and held several senior human resources executive positions with Pfizer Inc. She currently serves on the board of directors at Agios, Resilience Inc. and Stanford Health Care, a hospital and healthcare system; on the board of trustees and the human resources committee of Spelman College; and chairs the Glide Memorial Foundation Board of Trustees. She received her BBA in business administration from Baruch College of the City University of New York and her MBA from Columbia University Graduate School of Business.

Michael A. Kelly is the Founder and President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business that he founded in January 2018. Previously, he was a senior executive of Amgen, Inc., where he most recently served as Senior Vice President, Global Business Services and Vice President & Chief Financial Officer, International Commercial Operations. Mr. Kelly has also held positions at Tanox, Inc., Biogen, Inc. and Nutrasweet Kelco Company, a division of Monsanto Life Sciences. He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly received his B.Sc. in business administration from Florida A&M University, concentrating in finance and industrial relations.

### **Prime Medicine Expands Leadership Team With Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio**

July 28, 2022 – Prime Medicine, Inc. announced the expansion of the company's leadership team with the appointments of the following executives:

- Richard Brudnick as Chief Business Officer
- Niamh Alix as Chief Human Resources Officer
- Fubao Wang, Ph.D., as Senior Vice President, Head of Regulatory

"Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission," said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine. "These esteemed leaders have deep expertise across their respective focus areas, each of which is key to the advancement of our novel Prime Editing technology."

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / [andrew@barwicki.com](mailto:andrew@barwicki.com)  
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information regarding is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, internet, company website and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail  
U.S. Postage Paid  
Garden City, NY  
Permit No. 431

# Prime Medicine, Inc.

NASDAQ: PRME

**WWW.PRIMEMEDICINE.COM**

---

Barwicki Investor Relations \* 30 Wall Street, 8 FL \* New York, NY 10005

Deliver to: